Name: CRBP Income Statement - Corbus Pharmaceuticals Holdings. Revenue & EPS | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Revenue, Cost of Revenue, Gross Profit, Operating Expenses, Operating Income, Net Income, EPS Basic, EPS Diluted

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

CRBP - Corbus Pharmaceuticals Holdings. Inc.

USD | NASDAQ | Healthcare

CRBP Income Statement - Corbus Pharmaceuticals Holdings. Revenue & EPS | Ledgeburg

(in millions of USD, except per-share data)	Q1 FY 26	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q4 FY 24	Q3 FY 24	Q2 FY 24	Q1 FY 24	Q4 FY 23	Q3 FY 23	Q2 FY 23	Q1 FY 23	Q4 FY 22	Q3 FY 22	Q2 FY 22	Q1 FY 22	Q4 FY 21	Q3 FY 21	Q2 FY 21	Q1 FY 21	Q4 FY 20	Q3 FY 20	Q2 FY 20	Q1 FY 20	Q4 FY 19	Q3 FY 19	Q2 FY 19	Q1 FY 19	Q4 FY 18	Q3 FY 18	Q2 FY 18	Q1 FY 18	Q4 FY 17	Q3 FY 17	Q2 FY 17	Q1 FY 17	Q4 FY 16	Q3 FY 16	Q2 FY 16
Revenues
Revenues	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.0	-

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD, except per-share data)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013
Revenues
Revenues	-	-	-	-	0.0	0.9	3.9	36.1	4.8	2.4	1.9	0.6	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses
Research & Development	74.3	70.1	32.2	31.2	16.1	36.4	98.3	89.6	48.6	26.0	15.4	5.9	1.3	0.2
Operating Income
Operating Income	(89.8)	(85.3)	(48.7)	(45.1)	(39.8)	(56.0)	(122.8)	(77.1)	(56.7)	(32.6)	(20.0)	(8.9)	(2.6)	(0.6)
Non-Operating
Interest Income	-	-	-	-	-	-	-	1.2	1.0	-	-	0.0	0.0	0.0
Interest Expense
Tax & Net
Income Tax Expense	-	0.0	0.0	-	-	-	-	-	-	-	-	-	-	-
Net Income From Continuing Ops
Per Share
EPS Basic	(4.52)	(5.90)	(3.68)	(10.31)	(10.15)	(11.15)	(1.42)	-	-	-	-	-	-	-
EPS Diluted
Supplementary Data
EBITDA	(89.6)	(85.1)	(48.1)	(44.4)	(39.1)	(55.0)	(121.7)	(76.4)	(56.3)	(32.3)	(19.9)	(8.8)	(2.6)	-
EBIT

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

Operating Expenses
Research & Development	19.8	18.4	20.9	15.2	15.6	8.8	10.8	6.9	5.8	7.0	6.6	4.2	13.4	6.2	4.1	2.5	3.3	5.8	8.7	11.3	10.7	16.1	27.5	30.7	23.9	23.5	22.2	22.2	21.8	15.8	12.8	10.3	9.8	8.3	5.6	5.8	6.4	5.4	4.3	3.6
Selling General & Administrative	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Selling & Marketing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General & Administrative	4.5	3.6	3.6	4.0	4.1	3.8	4.7	4.1	3.9	3.1	2.9	3.9	3.9	4.6	4.1	4.8	5.2
Depreciation & Amortization	0.0	(0.0)	0.1	0.1	0.1	0.0	0.2	0.2	0.2	0.1	0.2	0.2	0.2	0.2	0.2	0.2
Amortization of Intangibles	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	-	-	-	-	-	-	0.0	0.0	2.5	-	0.1	0.0	-	-	-	-	-
Total Operating Expenses	24.3	22.0	24.4	19.2	19.8	12.6	15.5	11.0	9.6	10.1	9.5	8.2	17.3	10.8	8.2	12.3

Operating Income
Operating Income	(24.3)	(22.0)	(24.4)	(19.2)	(19.8)	(12.6)	(15.5)	(11.0)	(9.6)	(10.1)	(9.5)	(8.2)	(17.3)	(10.8)	(8.2)	(12.3)	(8.5)	(10.0)	(13.9)	(16.7)	(15.4)	(20.8)	(34.0)	(38.1)	(29.9)	(27.2)	(25.1)	1.7	(26.5)	(17.6)	(14.9)	(12.4)	(11.9)	(10.9)	(7.0)	(7.3)	(7.5)	(7.6)	(5.3)	(4.2)

Tax & Net
Income Tax Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income From Continuing Ops	(23.0)	(20.6)	(23.3)	(17.7)	(17.0)	(9.5)	(13.8)	(10.0)	(6.9)	(8.0)	(10.1)	(8.8)	(17.7)	(10.9)	(8.8)	(13.2)	(9.4)
Net Income From Discontinued Ops	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	(23.0)	(20.6)	(23.3)	(17.7)	(17.0)	(9.5)	(13.8)	(10.0)	(6.9)	(8.0)	(10.1)	(8.8)	(17.7)	(10.9)	(8.8)	(13.2)	(9.4)
Net Income Attributable To Parent	(23.0)	(20.6)	(23.3)	(17.7)	(17.0)	(9.5)	(13.8)	(10.0)	(6.9)	(8.0)	(10.1)	(8.8)	(17.7)	(10.9)	(8.8)	(13.2)
Less: Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Less: Preferred Dividends	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income To Common Shareholders	(23.0)	(20.6)	(23.3)	(17.7)	(17.0)	(9.5)	(13.8)	(10.0)	(6.9)	(8.0)	(10.1)	(8.8)	(17.7)	(10.9)	(8.8)

Per Share
EPS Basic	(1.23)	-	(1.90)	(1.44)	(1.39)	-	(1.15)	(0.90)	(0.83)	-	(2.27)	(2.05)	(4.24)	-	(2.11)	(3.18)	(2.26)	-	(0.02)	(0.15)	(0.14)	-	(0.43)	(0.52)	-	-	-	0.03	-	-	-	(0.21)	-	-	-	-	-	-	-	-
EPS Diluted	(1.23)	-	(1.90)	(1.44)	(1.39)	-	(1.15)	(0.90)	(0.83)	-	(2.27)	(2.05)	(4.24)	-	(2.11)	(3.18)	(2.26)	-
Shares Basic	18.7	-	12.3	12.2	12.2	-	12.0	11.1	8.3	-	4.4	4.3	4.2	-	4.2	4.2	4.2	-
Shares Diluted	18.7	-	12.3	12.2	12.2	-	12.0	11.1	8.3	-	4.4	4.3	4.2	-	4.2	4.2	4.2	-

Supplementary Data
EBITDA	(24.3)	(22.0)	(24.3)	(19.1)	(19.7)	(12.6)	(15.3)	(10.8)	(9.5)	(10.0)	(9.3)	(8.0)	(17.1)	(10.6)	(8.0)	(12.1)	(8.3)	(9.8)	(13.6)	(16.4)	(15.1)	(20.5)	(33.8)	(37.8)	(29.6)	(26.9)	(24.9)	1.9	(26.4)	(17.4)	(14.8)	(12.3)	(11.8)	(10.8)	(6.8)	(7.3)	(7.4)	(7.5)	(5.3)	(4.2)
EBIT	(24.3)	(22.0)	(24.4)	(19.2)	(19.8)	(12.6)	(15.5)	(11.0)	(9.6)	(10.1)	(9.5)	(8.2)	(17.3)	(10.8)	(8.2)	(12.3)	(8.5)	(10.0)	(13.9)